Clinical Trials

Adalimumab in psoriasis: The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL)

Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here